The Medication Guidelines for Neuropathic Pain Including Fibromyalgia is justified from a Scientific Viewpoint, However, it does Not Necessarily Agree with Clinical Priority
Received Date: Feb 25, 2018 / Accepted Date: Mar 12, 2018 / Published Date: Mar 16, 2018
The medication guidelines for fibromyalgia (FM) and neuropathic pain (NP) were mainly based on scientific evidence of analgesic efficacy in the literature. From a scientific viewpoint, it is justified, however, it does not necessarily agree with clinical priority. Adverse effects slightly affect these guidelines. Most adverse effects that were considered in the development of guidelines for NP including FM were short-term adverse effects such as drowsiness, nausea, vomiting, diarrhea, constipation, dysuria, and dry mouth. However, the long-term adverse effects such as cognitive dysfunction, dependence or abuse, sexual dysfunction, fracture, and osteoporosis also should be considered in medication. The adverse effects of pregabalin are cognitive dysfunction, dependence or abuse, obesity, marked drowsiness (sometimes loss of consciousness), and an expensive drug price. The adverse effects of duloxetine are cognitive dysfunction, dementia, sexual dysfunction, and bleeding and the drug price is expensive. Tricyclic antidepressants are safer than serotonin noradrenaline reuptake inhibitors in terms of dementia or cognitive dysfunction. The price of amitriptyline is inexpensive and most adverse effects except obesity disappear as soon as it is discontinued. Many studies have shown the analgesic effect of amitriptyline in FM and NP. However, scientific evidence of efficacy is low, because they are old studies. In clinical practice, efficacy based on personal experience, adverse effects based on personal experience and scientific evidence, drug price, and degree of offlabel use in addition to scientific evidence of efficacy should be reflected in the order of priority. Pregabalin and duloxetine should be administered after amitriptyline in medication treatment for NP including FM.
Keywords: Fibromyalgia; Neuropathic pain; Medication guideline
Citation: Toda K (2018) The Medication Guidelines for Neuropathic Pain Including Fibromyalgia is justified from a Scientific Viewpoint, However, it does Not Necessarily Agree with Clinical Priority. Fibrom Open Access 3: 128.
Copyright: © 2018 Toda K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Open Access Journals
- Total views: 2373
- [From(publication date): 0-2018 - Sep 27, 2021]
- Breakdown by view type
- HTML page views: 2122
- PDF downloads: 251